EP
OPNT

Eversept Partners’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Eversept Partners’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-13,901
Closed -$201K – 65
2018
Q4 		$201K Buy
+13,901
New +$227K 0.11% 51

Other funds holding OPNT

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FM
Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Eversept Partners's OPNT Position: Q1 2019 in Review

Eversept Partners sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2019, closing a stake of 13,901 shares — an estimated $201K sold.

Eversept Partners first reported a position in OPNT in Q4 2018 and held it in 1 quarter. The position peaked at $201K in Q4 2018. 23 funds tracked by Wall St. Rank hold OPNT as of Q1 2019.

  • Eversept Partners reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Eversept Partners sold 13,901 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2019, an estimated $201K.
  • Eversept Partners first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Eversept Partners's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $201K in Q4 2018.
  • 23 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2019.

Based on Eversept Partners's 13F filing for Q1 2019, filed 14 May 2019.